|
1
|
Ridge CA, Pua BB and Madoff DC:
Epidemiology and staging of renal cell carcinoma. Semin Intervent
Radiol. 31:3–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chow WH, Devesa SS, Warren JL and Fraumeni
JF Jr: Rising incidence of renal cell cancer in the United States.
JAMA. 281:1628–1631. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Escudier B, Porta C, Schmidinger M,
Rioux-Leclercq N, Bex A, Khoo V, Gruenvald V and Horwich A: ESMO
Guidelines Committee: Renal cell carcinoma: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27
Suppl 5:v58–v68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Collins I and Workman P: New approaches to
molecular cancer therapeutics. Nat Chem Biol. 2:689–700. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang XY, Jiang SQ, Zhang L, Liu QN and
Gong PL: Inhibitory effect of dauricine on inflammatory process
following focal cerebral ischemia/reperfusion in rats. Am J Chin
Med. 35:477–486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Law BY, Chan WK, Xu SW, Wang JR, Bai LP,
Liu L and Wong VK: Natural small-molecule enhancers of autophagy
induce autophagic cell death in apoptosis-defective cells. Sci Rep.
4:55102014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li P, Nijhawan D, Budihardjo I,
Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c
and dATP-dependent formation of Apaf-1/caspase-9 complex initiates
an apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu Y, Benedict MA, Ding L and Núñez G:
Role of cytochrome c and dATP/ATP hydrolysis in
Apaf-1-mediated caspase-9 activation and apoptosis. EMBO J.
18:3586–3595. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu R, Yu BX, Chen JF, Lv XY, Yan ZJ, Cheng
Y and Ma Q: Anti-tumor effects of atractylenolide I on bladder
cancer cells. J Exp Clin Cancer Res. 35:402016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kanesvaran R and Tan MH: Targeted therapy
for renal cell carcinoma: The next lap. J Carcinog. 13:32014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Derosa L, Albiges L, Massard C, Loriot Y,
Fizazi K and Escudier B: Safety of available treatment options for
renal cell carcinoma. Expert Opin Drug Saf. 15:1097–1106. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He QY, Meng FH and Zhang HQ: Reduction of
doxorubicin resistance by tetrandrine and dauricine in
harringtonine-resistant human leukemia (HL60) cells. Zhongguo Yao
Li Xue Bao. 17:179–181. 1996.(In Chinese). PubMed/NCBI
|
|
13
|
Marshall SJ, Russell PF, Wright CW,
Anderson MM, Phillipson JD, Kirby GC, Warhurst DC and Schiff PL Jr:
In vitro antiplasmodial, antiamoebic, and cytotoxic activities of a
series of bisbenzylisoquinoline alkaloids. Antimicrob Agents
Chemother. 38:96–103. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qian JQ: Cardiovascular pharmacological
effects of bisbenzylisoquinoline alkaloid derivatives. Acta
Pharmacol Sin. 23:1086–1092. 2002.PubMed/NCBI
|
|
15
|
Li YH and Gong PL: Neuroprotective effects
of dauricine against apoptosis induced by transient focal cerebral
ischaemia in rats via a mitochondrial pathway. Clin Exp Pharmacol
Physiol. 34:177–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang XD, Zhou X and Zhou KY: Dauricine
inhibits insulin-like growth factor-I-induced hypoxia inducible
factor 1alpha protein accumulation and vascular endothelial growth
factor expression in human breast cancer cells. Acta Pharmacol Sin.
30:605–616. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salazar-Roa M and Malumbres M: Fueling the
cell division cycle. Trends Cell Biol. 27:69–81. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang Z, Li C, Wang X, Zhai C, Yi Z, Wang
L, Liu B, Du B, Wu H, Guo X, et al: Dauricine induces apoptosis,
inhibits proliferation and invasion through inhibiting NF-kappaB
signaling pathway in colon cancer cells. J Cell Physiol.
225:266–275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brenner C, Galluzzi L, Kepp O and Kroemer
G: Decoding cell death signals in liver inflammation. J Hepatol.
59:583–594. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang L, Wu J, Ling MT, Zhao L and Zhao
KN: The role of the PI3K/Akt/mTOR signalling pathway in human
cancers induced by infection with human papillomaviruses. Mol
Cancer. 14:872015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Porta C and Figlin RA:
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney
cancer, and the therapeutic potential of
phosphatidylinositol-3-kinase/Akt inhibitors. J Urol.
182:2569–2577. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Faes S and Dormond O: PI3K and AKT:
Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
